Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trials
出版年份 2023 全文链接
标题
Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trials
作者
关键词
-
出版物
ANNALS OF ONCOLOGY
Volume -, Issue -, Pages -
出版商
Elsevier BV
发表日期
2023-01-19
DOI
10.1016/j.annonc.2023.01.004
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Long-Term Outcomes of Targeted Therapy after First-Line Immunotherapy in BRAF-Mutated Advanced Cutaneous Melanoma Patients—Real-World Evidence
- (2022) Paweł Rogala et al. Journal of Clinical Medicine
- The NADINA trial: A multicenter, randomised, phase 3 trial comparing the efficacy of neoadjuvant ipilimumab plus nivolumab with standard adjuvant nivolumab in macroscopic resectable stage III melanoma.
- (2022) Minke W. Lucas et al. JOURNAL OF CLINICAL ONCOLOGY
- Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial
- (2022) Irene L. M. Reijers et al. NATURE MEDICINE
- Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma
- (2021) E. A. Rozeman et al. NATURE MEDICINE
- Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)
- (2021) Alexander M. Menzies et al. NATURE MEDICINE
- Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma
- (2021) Joris L. Vos et al. Nature Communications
- Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial
- (2020) Reinhard Dummer et al. LANCET ONCOLOGY
- Pembrolizumab for Early Triple-Negative Breast Cancer
- (2020) Peter Schmid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neoadjuvant checkpoint blockade for cancer immunotherapy
- (2020) Suzanne L. Topalian et al. SCIENCE
- Long-term survival from pembrolizumab (pembro) completion and pembro retreatment: Phase III KEYNOTE-006 in advanced melanoma.
- (2020) Georgina V. Long et al. JOURNAL OF CLINICAL ONCOLOGY
- Learning from clinical trials of neoadjuvant checkpoint blockade
- (2020) Judith M. Versluis et al. NATURE MEDICINE
- Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers
- (2020) Myriam Chalabi et al. NATURE MEDICINE
- Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial
- (2020) Alexander M. M. Eggermont et al. JOURNAL OF CLINICAL ONCOLOGY
- Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial
- (2020) Paolo A Ascierto et al. LANCET ONCOLOGY
- Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial
- (2020) Nick van Dijk et al. NATURE MEDICINE
- Timing of neoadjuvant immunotherapy in relation to surgery is crucial for outcome
- (2019) Jing Liu et al. OncoImmunology
- A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma
- (2019) Alexander C. Huang et al. NATURE MEDICINE
- Early Recurrence in Completely Resected IIIB and IIIC Melanoma Warrants Restaging Prior to Adjuvant Therapy
- (2019) Martine Bloemendal et al. ANNALS OF SURGICAL ONCOLOGY
- Pathological response and survival with neoadjuvant therapy in melanoma: A pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC).
- (2019) Alexander M. Menzies et al. JOURNAL OF CLINICAL ONCOLOGY
- Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial
- (2019) Elisa A Rozeman et al. LANCET ONCOLOGY
- Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma
- (2018) M T Tetzlaff et al. ANNALS OF ONCOLOGY
- Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
- (2018) Alexander M.M. Eggermont et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
- (2018) Patrick M. Forde et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma
- (2018) Rodabe N. Amaria et al. NATURE MEDICINE
- Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma
- (2018) Christian U. Blank et al. NATURE MEDICINE
- Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)
- (2017) Jacob Schachter et al. LANCET
- Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
- (2017) Jeffrey Weber et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
- (2016) Alexander M.M. Eggermont et al. NEW ENGLAND JOURNAL OF MEDICINE
- Outcome After Therapeutic Lymph Node Dissection in Patients with Unknown Primary Melanoma Site
- (2011) Sebastiaan P. Prens et al. ANNALS OF SURGICAL ONCOLOGY
- Site and Timing of First Relapse in Stage III Melanoma Patients: Implications for Follow-Up Guidelines
- (2010) Emanuela Romano et al. JOURNAL OF CLINICAL ONCOLOGY
- National Assessment of Melanoma Care Using Formally Developed Quality Indicators
- (2009) Karl Y. Bilimoria et al. JOURNAL OF CLINICAL ONCOLOGY
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started